Effects of Diquafosol Sodium Eye Drops on Tear Film Stability in Short BUT Type of Dry Eye

Shimazaki-Den, Seika; Iseda, Hiroyuki; Doğru, Murat; Shimazaki, Jun

doi:10.1097/ico.0b013e3182930b1d

Cited by 60 publications

(46 citation statements)

References 18 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies compared 3% diquafosol with preservative-free artificial tears [17, 19]. One study examined 0.9% normal saline [11] and 1 study used placebo eye drops [15].…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials

Nam

Kim

Yoo³

2019

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: A meta-analysis was performed to evaluate the safety and efficacy of topical 3% diquafosol in treating patients with dry eye disease (DED). Methods: Nine qualified randomized controlled trials incorporating 1,467 patients were included. Two of the reviewers selected the studies and independently assessed the risk of bias. The outcome measures were Schirmer score, tear film break-up time (TFBUT), rose bengal staining score, and corneal fluorescein staining score. To confirm the effect of diquafosol on dryness after cataract surgery, we performed a subgroup analysis according to the presence or absence of surgery. Results: We observed statistically significant improvements in scores on the Schirmer test (weighted mean difference 0.74 mm at 4 weeks; 95% CI: 0.24–1.24; I² = 0%), fluorescein stain, rose bengal stain, and TFBUT after treatment with diquafosol compared with the group using other eye drops. As a result of the subgroup analysis of DED after cataract surgery, diquafosol was found to be more effective than the other eye drops with regard to TFBUT and rose bengal staining. Conclusions: Topical diquafosol could be an effective treatment for DED, and also for DED after cataract surgery. Further randomized controlled trials with larger sample sizes for the different clinical types of DED are warranted to determine the efficacy and limitations of diquafosol for these different clinical types of DED.

show abstract

“…Two studies compared 3% diquafosol with preservative-free artificial tears [17, 19]. One study examined 0.9% normal saline [11] and 1 study used placebo eye drops [15].…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials

Nam

Kim

Yoo³

2019

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…Previous reports suggested that short BUT-type dry eye is associated with allergic conjunctivitis 43 and a decreased mucin level in tear fluid. 44 In fact, this case was complicated with perennial allergic conjunctivitis, so the manifestation of this case might have been caused by allergic conjunctivitis rather than lacrimal gland dysfunction. Diquafosol ophthalmic solution reportedly is effective in improving short BUTtype dry eye, 44 and this case also responded well to the Figure 4 Slit-lamp photographs of the right eye of a 54-year-old female with aqueous tear-deficient dry eye with SS.…”

Section: Discussionmentioning

confidence: 99%

“…44 In fact, this case was complicated with perennial allergic conjunctivitis, so the manifestation of this case might have been caused by allergic conjunctivitis rather than lacrimal gland dysfunction. Diquafosol ophthalmic solution reportedly is effective in improving short BUTtype dry eye, 44 and this case also responded well to the Figure 4 Slit-lamp photographs of the right eye of a 54-year-old female with aqueous tear-deficient dry eye with SS. The fluorescein staining of the cornea and conjunctiva was markedly improved at 6 and 12 months after the start of the treatment with 3% diquafosol ophthalmic solution in comparison to at baseline.…”

Section: Discussionmentioning

confidence: 99%

Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren’s syndrome

Yokoi

Sonomura

Katô

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To investigate the long-term results of 3% diquafosol ophthalmic solution as an alternative therapy to existing ophthalmic solutions, including topical immunosuppression, for the treatment of dry eye in patients with Sjögren's syndrome. Methods This study involved 14 female dryeye patients (mean age: 62.4 years) with Sjögren's syndrome who insufficiently responded to their current therapy. In all patients, 3% diquafosol ophthalmic solution was administered six times daily for 12 months in substitution for artificial tears and sodium hyaluronate ophthalmic solution. Their use of corticosteroid eye drops remained unchanged from that prior to the treatment with diquafosol sodium. The subjective symptoms assessed, and ocular signs including tear meniscus radius and the tear film breakup time, and ocular-surface epithelial damage score were examined at 1, 2, 3, 4, 5, 6, 9, and 12 months after initiating treatment. Results Among the subjective symptoms, significant improvement was obtained in dryness at 2 months post treatment, in eye fatigue at 1, 2, 3, 4, and 12 months post treatment, and in pain at 1, 2, 6, and 12 months post treatment. Difficulty in opening the eye, foreign body sensation, and redness were also significantly ameliorated at various time-points. The tear meniscus radius and the tear film breakup time were significantly improved throughout the observation period, and the corneal epithelial staining scores were significantly decreased at 3 months post treatment. ConclusionsIn dry-eye patients with Sjögren's syndrome, treatment with 3% diquafosol ophthalmic solution improved both symptoms and signs, and that effectiveness was maintained for 12 months.

show abstract

“…Topical instillation of DQS ophthalmic solution is reportedly effective for various types of dry eye, including aqueous tear-deficient dry eye 38 with a Schirmer test value of ≤ 5 mm (eg, SS), short BUT type dry eye, 39 dry eye after surgery, [40][41][42] and obstructive meibomian gland dysfunction. 43 The possible mechanism of that action is that DQS ophthalmic solution increases tear-film stability, thus eliminating the vicious cycle (the core mechanism of dry eye on the ocular surface) by increasing fluid secretion, mucin secretion, and membrane-binding mucin gene expression.…”

Section: Discussionmentioning

confidence: 99%

The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjögren’s syndrome: a pilot study

Yokoi

Katô

Kinoshita

2016

Eye

View full text Add to dashboard Cite

Purpose To investigate the effect of 3% diquafosol sodium ophthalmic solution (DQS) on aqueous tear volume increase in dry-eye patients with Sjögren's syndrome (SS). Methods In this pilot study, 17 dry-eye patients with SS (1 male and 16 females; mean age: 66.4 years) were enrolled and underwent topical instillation of two ophthalmic solutions, artificial tears (AT) in one eye and DQS in the fellow eye, in a masked manner. The central lower tear meniscus radius (TMR) curvature was measured before and at 15 min after instillation by video-meniscometry. Simultaneously, all patients self-evaluated their symptoms of wetness and stinging using a visual analog scale (VAS, in millimeters). Results Topical instillation of DQS significantly increased the TMR at 15 min (mean: 0.21 ± 0.08 (SD) mm) compared with at baseline (mean: 0.16 ± 0.07 mm) (Po0.001, paired t-test), whereas AT had no effect at baseline (mean: 0.18 ± 0.09 mm) or at 15 min (mean: 0.18 ± 0.09 mm). The visual VAS score of wetness at 15-min post-instillation increased in both groups compared with at baseline. In the DQS-treated eyes, the postinstillation change in TMR from baseline was not correlated with the baseline value of the Schirmer test, corneal staining score, or conjunctival staining score. Conclusions Topical instillation of DQS increased aqueous tear volume on the ocular surface of dry-eye patients with SS, with its action being independent of lacrimal gland function.

show abstract

Effects of Diquafosol Sodium Eye Drops on Tear Film Stability in Short BUT Type of Dry Eye

Abstract: DQS improved subjective symptoms and prolonged BUT in eyes with UTF not associated with low tear secretion and ocular surface epithelial damage. Because many patients who have UTF are refractory to conventional treatments, DQS may offer benefits in the treatment of dry eyes.

Cited by 60 publications

References 18 publications

Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials

Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials

Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren’s syndrome

The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjögren’s syndrome: a pilot study

Contact Info

Product

Resources

About